Cannabinoids for Pain Management and Neuroprotection From Concussion
A legfontosabb adatok
- Ki végzi
- University of Regina
- Hol
- Kanada2 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Befejeződött
- Fázis
- 1. fázis
- Résztvevők
- 34 fő vett részt
- Kezdés
- 2024. febr. 15.
- Befejezés
- 2024. nov. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Cannabis/Hemp Isolate Extract
- A regiszteradat frissítve
- 2026. május 6.
Ki vehet részt
- Életkor
- 18 év – 35 év
- Nem
- Csak férfiak
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Healthy male adults between 18-35 years of age that compete in contact sport athletics
- No known cerebrovascular or cardiovascular complications
- Not habitual recreational users of cannabis (i.e., <1 day/week) or tobacco users
- Agree not to consume any other cannabis or tobacco products while enrolled in the study
- Agree to list any prescription medications being taken
- Ability to maintain commitment to all proposed biopsychological and health questionnaires, and neuro-physiological, physiological, perceptual-cognitive, and functional motor skills laboratory tests
Ki nem vehet részt
- Use of cannabis-based therapy within 2 months (participants who have previously used a cannabis based therapy may be included if they have a 2 month period without use of cannabis based therapy prior to enrolment in the study)
- Initiation or dosage change of oral or injected steroids within past 3 months
- Medically supervised for anxiety, depression, or other neurological conditions
- Allergy or known intolerance to any of the compounds within the study preparation
- Inability to attend assessments on a regular basis at the pre-determined times, or failure to take drug on a daily basis
- Clinically significant cardiac, renal or hepatic disease (as assessed by the site investigator)
- Female
- Requirement to travel to the USA during study period; USA laws do not permit cross border with cannabis products
- Any level of cannabis in blood samples when sampled at the commencement of the study
- Concussion
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The goal of this open-label, placebo-controlled, dosage escalation study is to learn about the safety of a Cannabis/Hemp Isolate Extract in normal healthy adults engaged in elite contact sport competition.
A teljes eredeti leírásKevesebb
The main question it aims to answer is:
• Are cannabis/hemp-based products with high CBD safe, well-tolerated and without adverse physiological and psychological dysfunction, when administered on a daily basis?
Participants will:
* be given CBD and a placebo. The placebo will be taken for 2 weeks prior to starting the CBD. Participants will start on a low dose of CBD, beginning at 5 mg CBD/kg body mass, which will be increased by 5 mg/kg every 2-weeks until 30 mg CBD/kg body mass is taken; * have blood samples taken to analyse how much CBD is used in the body and for how long it lasts in the body (pharmacokinetics and pharmacodynamics); * have saliva samples collected for genetic analysis; * undergo testing sessions, which will include psychological and health questionnaires, equipment to record signals from the brain and heart, and safety laboratory tests.
A vizsgálat csoportja
- Dose EscalationA vizsgált kezelés
When participants start the CBD, they will be started on a low dose of CBD, beginning at 5 mg CBD/kg body mass, and then increased by 5 mg/kg every 2-weeks until 30 mg CBD/kg body mass is taken.
Kezelés: Cannabis/Hemp Isolate Extract
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Naturally Produced Cannabinoids for Pain Management and Neuroprotection From Concussion During Participation in Contact Sports: Dose Escalation
- Publikációk
- A regiszteradat frissítve
- 2026. május 6.